Employee share option scheme
Oslo, 21 June 2019 – In accordance with the authorisation granted by the Annual General Meeting 29 May 2019, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 320,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI […]
Minutes from Annual General Meeting 2019
Oslo, 29 May 2019. The Annual General Meeting in PCI Biotech Holding ASA took place today, 29 May 2019. All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 8 May 2019. The Board of Directors consists of the following members until the next Annual […]
First patient enrolled in the fimaChem pivotal RELEASE study
Oslo (Norway), 23 May 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced first patient enrolled in the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients. The pivotal RELEASE study has the potential of accelerated/conditional marketing approval […]